Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES-FISH: ivabradine for heart rate control in cardiogenic shock
2018-000191-15Phase 3Active
- Sponsor
- Ramon y Cajal Institute for Health Research
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ivabradine in cardiogenic shock, Acute Heart Failure (AHF), heart failure with reduced ejection fraction (HFrEF) and 1 more (2 arms), sponsored by Ramon y Cajal Institute for Health Research. Primary endpoint: Emergent adverse events. Started Apr 2018; status: active.
02
Drugs
ivabradine
03
Conditions
cardiogenic shockAcute Heart Failure (AHF)heart failure with reduced ejection fraction (HFrEF)coronary arteriosclerosis
Beyond the preview
Go deeper on 2018-000191-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000191-15.